18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          MicroRNAs are a class of small non-coding RNAs that regulate the expressions of many genes. Previously, we found that the expression of p55PIK, an isoform of phosphatidylinosotol 3-kinase that has important roles in the regulation of cell cycle, is increased significantly in several types of cancer and contributes to the tumor growth. However, the mechanism for this increased p55PIK expression is not well understood. In this study, we show that miR-148b binds specifically to the 3'-untranslated region of p55PIK and significantly suppresses p55PIK expression. MiR-148b overexpression abolished p55PIK stimulation of cell proliferation and cell cycle progression in colorectal cancer (CRC) cell lines and decreased tumor growth in vivo. Furthermore, we demonstrated that p53 directly activates the transcription of miR-148b by binding to its promoter. In CRC cell lines and tissues, p53 expression was associated with miR-148b expression, and both were negatively associated with p55PIK expression. Our study shows that the p53/miR-148b/p55PIK axis has an important role in cell proliferation and tumor growth, and may represent a novel therapeutic target for treating cancers containing p53 mutations or losses.

          Related collections

          Author and article information

          Journal
          Oncogene
          Oncogene
          1476-5594
          0950-9232
          Feb 12 2015
          : 34
          : 7
          Affiliations
          [1 ] Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
          [2 ] Department of Molecular Medical Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
          [3 ] Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
          [4 ] Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
          Article
          onc201430
          10.1038/onc.2014.30
          24632606
          f8a5b2d2-8905-4d4b-9b51-f83d5e828a70
          History

          Comments

          Comment on this article